As a Medical Safety Officer at CPC, Dr. Galinkin is integral in providing safety oversight to clinical trials that CPC manages. He helps ensure adherence to the clinical study protocol including clarification of inclusion/exclusion criteria, drug interactions, assessment of subject discontinuation, protocol deviations, and overall conduct of the study. Additionally, Dr. Galinkin serves as a member of the FDA Anesthetic and Analgesic Drug Products Advisory Committee.
Concurrently, he is Professor of Anesthesiology and Pediatrics at the University of Colorado Denver with an appointment at Children’s Hospital Colorado since 2003. He has served on the Colorado Multiple Institutional Review Board (COMIRB) since 2003 and currently chairs one of the review panels.
Dr. Galinkin is also the Medical Director of iC42, a state-of-the art analytical mass spectrometry facility (17 mass spectrometers, cGLP compliant, CAP accredited and CLIA certified) affiliated with CPC. He is an expert in mass-spectrometry based analytics, clinical study design, conduct and analysis.
Dr. Galinkin’s research has focused primarily in pediatric pain management which has led to both NIH funding and industry sponsorship. His recent efforts have specifically focused on the developmental pharmacokinetics and pharmacogenomics of opioids across the pediatric spectrum.
Selected to the Marquis Who’s Who in America since 2009 and Best Doctors® since 2007, Dr. Galinkin is widely recognized as a Key Opinion Leader in the fields of anesthesiology, pediatrics and bioanalytics. Additionally, Dr. Galinkin serves on the American Academy of Pediatrics Committee on Drugs and as a reviewer for a variety of journals including Clinical Pharmacology and Therapeutics, Journal of Anesthesia, Journal of Separation Science and Methods, Medical and Pediatric Oncology, and Findings in Experimental and Clinical Pharmacology.
Prior to moving to Denver, Dr. Galinkin was on staff with Children’s Hospital of Philadelphia (CHOP) for over 6 years. During his time at CHOP he served as the Associate Director of the Pediatric Pharmacology Research Unit and developed a network of collaborators to assist in drug development and analytic studies for children.